Advertisement

Genedata’s newsest Deep Learning for High Content Screening (HCS) platform enables pharmaceutical R&D organizations to reduce the time it takes—by more than half—to accurately classify HCS images and detect new phenotypes. Developed over the last few years in close collaboration with leading academic institutions and pharmaceutical R&D organizations, the deep learning technology uses convolutional neural networks (CNNs) to automatically analyze microscopy images in high throughput. Simplifying image analysis workflows, the solution significantly accelerates image analysis, provides high-quality classification results, broadens HCS applications, and enables the discovery of new phenotypes that are difficult to detect with classical analysis approaches. The HCS platform shortens projects, enables new phenotypic assays, and scales up HCS for untrained scientists.
Genedata
www.genedata.com, 877-436-3872

 

Advertisement
Advertisement